CTOR (Citius Oncology) Total Debt per Share : $0.00 (As of Sep. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Citius Oncology Total Debt per Share?

$0.00 (As of Sep. 2023)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Citius Oncology's Total Debt Per Share for the quarter that ended in Sep. 2023 was $0.00.

Citius Oncology Total Debt per Share Historical Data

The historical data trend for Citius Oncology's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Citius Oncology Total Debt per Share Chart

Citius Oncology Annual Data

Trend

Sep22

Total Debt per Share

Citius Oncology Semi-Annual Data
	Sep22	Sep23
Total Debt per Share	-	-

Citius Oncology Total Debt per Share Calculation

Citius Oncology's Total Debt Per Share for the fiscal year that ended in Sep. 2022 is calculated as:

Total Debt Per Share	=	(Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation)	/	Shares Outstanding (EOP)
	=	(0.00	+	0.00)	/	71.24
	=	0.00

Citius Oncology's Total Debt Per Share for the quarter that ended in Sep. 2023 is calculated as:

Total Debt Per Share	=	(Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation)	/	Shares Outstanding (EOP)
	=	(0.00	+	0.00)	/	71.24
	=	0.00

Citius Oncology Total Debt per Share Related Terms

Thank you for viewing the detailed overview of Citius Oncology's Total Debt per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Citius Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Citius Oncology Inc (NAS:CTOR) » Definitions » Total Debt per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

420 Lexington Ave, Suite 2446, New York, NY, USA, 10170

Website

Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.